Redefining High-Risk NMIBC

This webinar was funded by AstraZeneca, but was developed independently by the speakers and AMJ. The content is intended for US Healthcare Professionals only.

For decades, high-risk non-muscle invasive bladder cancer (NMIBC) meant transurethral resection and Bacillus Calmette-Guérin (BCG). With an immunotherapy-based combination now FDA approved in BCG-naive disease, a urologic oncologist, a medical oncologist, and an advanced practice provider (APP) examine who stands to benefit, and why a new therapy alone won’t close the gap on recurrence and progression.

Key topics discussed:

• Where the current pathway breaks down, from missed maintenance to handoffs between urology and oncology
• What the POTOMAC Phase III data adds in BCG-naive disease, and the open questions on patient selection
• How immune-related adverse events change monitoring in urology, and what to teach patients to report
• What building a bladder program takes: standardized pathways, navigation, escalation triggers, and metrics

Chapters

1.  Welcome and Agenda: 00:00 – 01:36
2.  A System Problem: 01:36 – 06:01
3.  Where the Pathway Fails: 06:01 – 11:48
4.  Adding IO to BCG: 11:48 – 15:44
5.  Phase III Evidence: 15:44 – 21:49
6.  Immune-Related Adverse Events: 21:49 – 23:52
7.  Building a Bladder Program: 23:52 – 28:44
8.  The Evidence in NMIBC: 28:44 – 38:34
9.  BCG Response Categories: 38:34 – 40:56
10.  POTOMAC Trial: 40:56 – 49:29
11.  Safety and Toxicity: 49:29 – 52:39
12.  The APP Safety Net: 52:39 – 59:14
13.  Panel Question and Answer: 59:14 – 1:14:10
14.  Closing Takeaways: 1:14:10 – 1:15:30

1. Michigan Institute of Urology, St Clair Shores, Michigan, USA
2. Oakland University William Beaumont School of Medicine, Auburn Hills, Michigan, USA
3. Corewell Health, Grand Rapids, Michigan, USA
4. GU Oncology Program, University of California, Los Angeles, USA
5. GU Oncology Research Program, University of California, Los Angeles, USA
6. Urology Partners of North Texas, Arlington, USA